Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

[1]  M. Duffy,et al.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.

[2]  J. Foekens,et al.  Prognostic value of plasminogen activator inhibitor‐1 in head and neck squamous cell carcinoma , 2007, Head & neck.

[3]  J. Overgaard,et al.  Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. , 2007, Lung cancer.

[4]  B. Molnár,et al.  Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. , 2007, World journal of gastroenterology.

[5]  A. Roessner,et al.  The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. , 2007, Oncology reports.

[6]  H. Allgayer,et al.  Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms , 2007, Critical reviews in clinical laboratory sciences.

[7]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Diamandis,et al.  Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. , 2006, Biological chemistry.

[9]  Ge Li,et al.  Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer , 2006, BMC Cancer.

[10]  E. Diamandis,et al.  Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma , 2006 .

[11]  Y. Kodera,et al.  Plasminogen activator inhibitor‐1 as a potential marker for the malignancy of gastric cancer , 2006, Cancer science.

[12]  J. Kos,et al.  Intracellular proteolytic activity of cathepsin B is associated with capillary‐like tube formation by endothelial cells in vitro , 2006, Journal of cellular biochemistry.

[13]  H. Liang,et al.  Prognostic factors of young patients with colon cancer after surgery. , 2006, World journal of gastroenterology.

[14]  H. Allgayer,et al.  Urokinase system expression in gastric carcinoma , 2006, Cancer.

[15]  P. Catalano,et al.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Y. Kodera,et al.  Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer , 2005, British Journal of Cancer.

[17]  A. Roessner,et al.  Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture--regulation of cathepsin B expression and invasiveness. , 2005, Cancer letters.

[18]  Bonnie F. Sloane,et al.  Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells , 2005, Journal of Cell Science.

[19]  R. Koch,et al.  Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: A multivariate analysis , 2005, Journal of surgical oncology.

[20]  L. Lund,et al.  Plasminogen activation and cancer , 2005, Thrombosis and Haemostasis.

[21]  M. Mai,et al.  Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. , 2005, Anticancer research.

[22]  J. Iwamoto,et al.  Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori , 2005, Scandinavian journal of gastroenterology.

[23]  N. Harbeck,et al.  Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. , 2004, Anticancer research.

[24]  M. Duffy,et al.  Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression. , 2004, European journal of cancer.

[25]  A. Scorilas,et al.  Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. , 2004, Cancer letters.

[26]  J. Foekens,et al.  Predictive Impact of Urokinase-Type Plasminogen Activator , 2004, Cancer Research.

[27]  O. Nilsson,et al.  Prediagnostic Levels of Carcinoembryonic Antigen and CA 242 in Colorectal Cancer: A Matched Case-Control Study , 2003, Diseases of the colon and rectum.

[28]  C. Haglund,et al.  Serum HCGβ, CA 72‐4 and CEA are independent prognostic factors in colorectal cancer , 2002, International journal of cancer.

[29]  H. Höfler,et al.  Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[31]  R. Lamerz,et al.  Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. , 2000, Anticancer research.

[32]  P. Russell,et al.  Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.

[33]  H. Nielsen,et al.  Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer , 2000, Annals of surgical oncology.

[34]  Tatsuo Tanaka,et al.  Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size , 1999, Cancer.

[35]  P. Carreira,et al.  Survival of patients with colorectal carcinoma , 1999, Cancer.

[36]  Z. Tulassay,et al.  The role of cysteine and serine proteases in colorectal carcinoma , 1999, Cancer.

[37]  L A Carriquiry,et al.  Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? , 1999, Diseases of the colon and rectum.

[38]  N. Armitage,et al.  Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. , 1998, British Journal of Cancer.

[39]  H. Nielsen,et al.  Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Z. Tulassay,et al.  Cysteine and serine proteases in colorectal cancer , 1998 .

[41]  Z. Tulassay,et al.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role , 1997, Clinical & Experimental Metastasis.

[42]  F. Farinati,et al.  Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. , 1997, The American journal of gastroenterology.

[43]  M. Rugge,et al.  Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. , 1996, Carcinogenesis.

[44]  C. V. D. van de Velde,et al.  Prognostic value of the plasminogen activation system in patients with gastric carcinoma , 1996, Cancer.

[45]  G. Huet,et al.  Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. , 1995, Cancer letters.

[46]  M. Rugge,et al.  Cysteine and serine proteases in gastric cancer , 1995, Cancer.

[47]  P. Quax,et al.  Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. , 1994, Gastroenterology.

[48]  K. Becker,et al.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. , 1994, Cancer research.

[49]  T. Hirano,et al.  Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis. , 1993, Cancer letters.

[50]  K. Huber,et al.  Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. , 1993, Cancer research.

[51]  H. Verspaget,et al.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. , 1993, Gut.

[52]  J. Reynolds,et al.  The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .

[53]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[54]  Bonnie F. Sloane.  Cathepsin B and cystatins: evidence for a role in cancer progression. , 1990, Seminars in cancer biology.

[55]  F. Safi,et al.  The Clinical Relevance of Tumor Marker Cea, Ca 19-9 in Regional Chemotherapy of Hepatic Metastases of Colorectal Carcinoma , 1988, The International journal of biological markers.

[56]  H. Verspaget,et al.  Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. , 1987, Cancer research.

[57]  J. Northover,et al.  Carcinoembryonic antigen and recurrent colorectal cancer , 1985, The British journal of surgery.

[58]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.

[59]  T. Taguchi,et al.  Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient , 1980, Journal of surgical oncology.

[60]  F. R. Watson,et al.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates. , 1967, Annals of surgery.

[61]  J. Rudnicki,et al.  Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage. , 2006, Journal of experimental therapeutics & oncology.

[62]  C. V. D. van de Velde,et al.  Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. , 1997, British Journal of Cancer.